MLchartDataset catalogue

Koselugo

Term · Oncology and biomedicine · MLC-T-ONC-004660

A drug used to treat children aged 2 years and older with a rare genetic condition called neurofibromatosis type 1. It is used in patients who have plexiform neurofibromas that are causing symptoms and cannot be removed by surgery. It is also being studied in the treatment of some types of cancer. Koselugo blocks proteins called MEK1 and MEK2, which may help keep abnormal cells or cancer cells from growing. It is a type of kinase inhibitor. Also called AZD6244, MEK inhibitor AZD6244, and selumetinib sulfate.

Table 1. Record
IdentifierMLC-T-ONC-004660
FieldOncology and biomedicine
SynonymsAZD6244; MEK inhibitor AZD6244; selumetinib sulfate
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-004660",
  "term": "Koselugo",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat children aged 2 years and older with a rare genetic condition called neurofibromatosis type 1. It is used in patients who have plexiform neurofibromas that are causing symptoms and cannot be removed by surgery. It is also being studied in the treatment of some types of cancer. Koselugo blocks proteins called MEK1 and MEK2, which may help keep abnormal cells or cancer cells from growing. It is a type of kinase inhibitor. Also called AZD6244, MEK inhibitor AZD6244, and selumetinib sulfate.",
  "synonyms": [
    "AZD6244",
    "MEK inhibitor AZD6244",
    "selumetinib sulfate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/koselugo/"
}

Record 9,797 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.